This new tool, called Gallium PSMA (Prostate-Specific Membrane Antigen) , was produced on site using a computer-controlled automaton. The CHU Caen Normandie thus becomes the first center in western Normandy to produce this innovative drug, joining several leading medical centers around the world.
Gallium PSMA specifically targets prostate tumor cells, opening up new perspectives in terms of early detection, personalized treatment and therapeutic monitoring for patients with this cancer, the most common in men.
With this cutting-edge technology, doctors will be able to detect tumor boundaries with unparalleled accuracy, optimizing treatment strategies and reducing complications and side effects.
In addition, Gallium PSMA plays a crucial role in therapeutic monitoring by evaluating the cancer's response to treatment. This allows physicians to adjust treatment protocols in a reactive manner, providing personalized care and improving clinical outcomes. A first patient benefited from this technique on Friday June 16, 2023 at CHU Caen Normandie. This step marks a turning point in the field of Normandy nuclear medicine and positions the CHU Caen Normandie radiopharmacy unit as a pioneer in the field.
Professor Denis Agostini Nuclear Medicine & Theranostics Department , also highlights the CHU Caen Normandie's continued commitment to providing quality, state-of-the-art care to patients with prostate cancer and expresses his pride and his gratitude to the radiopharmacy team and especially the work of Dr. Jonathan Vigne and Dr. Maïté Esnault for this major breakthrough.
The CHU Caen Normandie, an expert referral institution in the region, remains determined to continue its efforts in the research and development of new diagnostic and therapeutic solutions to fight against prostate cancer and other serious diseases.
